Data at ESMO 22 key to progress for Gilead's ADC Trodelvy

Important new data for the antibody-drug conjugate (ADC) Trodelvy (sacituzumab govitecan-hziy) have been outlined ahead of their presentation at the annual meeting of the European Society of Medical Oncology (ESMO 22).

The results come from a post hoc subgroup analysis from the Phase III TROPiCS-02 study, which examines the impact of the therapy in the later-line treatment of breast cancer.

Looking at the important endpoint of progression-free survival (PFS), the analysis shows that Trodelvy improved median PFS in comparison with prescriber’s choice of chemo.